Longyong Xu,Fanglue Peng,Qin Luo,Yao Ding,Fei Yuan,Liting Zheng,Wei He,Sophie S Zhang,Xin Fu,Jin Liu,Ayse Sena Mutlu,Shuyue Wang,Ralf Bernd Nehring,Xingyu Li,Qianzi Tang,Catherine Li,Xiangdong Lv,Lacey E Dobrolecki,Weijie Zhang,Dong Han,Na Zhao,Eric Jaehnig,Jingyi Wang,Weiche Wu,Davis A Graham,Yumei Li,Rui Chen,Weiyi Peng,Yiwen Chen,Andre Catic,Zhibin Zhang,Bing Zhang,Anthony M Mustoe,Albert C Koong,George Miles,Michael T Lewis,Meng C Wang,Susan M Rosenberg,Bert W O'Malley,Thomas F Westbrook,Han Xu,Xiang H-F Zhang,C Kent Osborne,Jin Billy Li,Matthew J Ellis,Mothaffar F Rimawi,Jeffrey M Rosen,Xi Chen

Abstract:Chemotherapy is often combined with immune checkpoint inhibitor (ICIs) to enhance immunotherapy responses. Despite the approval of chemo-immunotherapy in multiple human cancers, many immunologically cold tumors remain unresponsive. The mechanisms determining the immunogenicity of chemotherapy are elusive. Here, we identify the ER stress sensor IRE1α as a critical checkpoint that restricts the immunostimulatory effects of taxane chemotherapy and prevents the innate immune recognition of immunologically cold triple-negative breast cancer (TNBC). IRE1α RNase silences taxane-induced double-stranded RNA (dsRNA) through regulated IRE1-dependent decay (RIDD) to prevent NLRP3 inflammasome-dependent pyroptosis. Inhibition of IRE1α in Trp53-/- TNBC allows taxane to induce extensive dsRNAs that are sensed by ZBP1, which in turn activates NLRP3-GSDMD-mediated pyroptosis. Consequently, IRE1α RNase inhibitor plus taxane converts PD-L1-negative, ICI-unresponsive TNBC tumors into PD-L1high immunogenic tumors that are hyper-sensitive to ICI. We reveal IRE1α as a cancer cell defense mechanism that prevents taxane-induced danger signal accumulation and pyroptotic cell death.

Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Supplementary Figure 3 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response Via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Supplementary Figure 1 from CAAT/Enhancer Binding Protein Homologous Protein–Dependent Death Receptor 5 Induction is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells

Supplementary Figures 6-7 from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer

Supplementary Figure 4 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 3 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Contribution of Rip3 and Mlkl to Immunogenic Cell Death Signaling in Cancer Chemotherapy

Supplementary Figure 5 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 5 from XIAP and PHB1 Regulate Anoikis Through Competitive Binding to TRAF6

Supplementary Figure 3 from XIAP and PHB1 Regulate Anoikis Through Competitive Binding to TRAF6